

## CORPORATE PROFILE


Dthera Sciences (OTCQB:DTHR), based in San Diego, Calif., is a digital therapeutics company focused on developing innovative quality of life therapies for the elderly and those suffering from cognitive decline. The Company's lead product, ReminX, is an artificial-intelligence-powered consumer health product designed to deliver reminiscence therapy digitally to individuals suffering from dementia from Alzheimer's disease and other neurodegenerative conditions, as well as for seniors experiencing social isolation. The company plans to launch ReminX commercially in the second quarter of 2018.

7310 Miramar Road Suite 350  
San Diego CA, 92126  
Phone: Tel: 858-215-6360  
<http://dthera.com>  
[IR@dthera.com](mailto:IR@dthera.com)

CORE IR  
377 Oak Street  
Garden City, NY 11530  
Tel: 516-222-2560  
[www.coreir.com](http://www.coreir.com)

## STOCK PERFORMANCE

Symbol	DTHR
Exchange	OTCQB
Market Cap.	8m
52 Week Range	3.00 - 20.00
Close	3.00
Volume	100
Shares Outstanding	2,667,602
As of Dec 14, 2018 1:50 pm	



## MANAGEMENT TEAM

**Edward Cox** - CEO

**Dave Keene** - CTO

## BOARD OF DIRECTORS

**Michael R. Feldschuh** - Director

**James A. Lombard** - Director

**Martin S. Wolpoff** - Director

**Edward S. Feuer** - Director

**Bernhard Saxe** - Director

**Jonathan Feldschuh** - Chief Scientific Officer

## RECENT HEADLINES

[Dec 13, 2018 - FDA Supports De Novo Pathway for Dthera Sciences' Breakthrough Alzheimer's Device](#)

[Dec 11, 2018 - Dthera Sciences to Provide Corporate Update at the Digital Medicine and Medtech Showcase](#)

[Oct 30, 2018 - Dthera Sciences Appoints Dr. Amir Kalali to Board of Directors](#)

[Sep 25, 2018 - Dthera Sciences Announces Reverse Split](#)

[Aug 30, 2018 - Dthera Sciences to Present at the 7th Annual Liolios Gateway Conference on September 5, 2018](#)

## PAST EVENTS

Dec 14, 2016 - Dthera Sciences Investor Presentation Live Webcast